SMSeyedeh Nasim Mirbahari

Seyedeh Nasim Mirbahari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Seyedeh Nasim Mirbahari has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Altered expression of ZAP70 and lnc-FAHD2B-3 in colorectal polyps: an exploratory molecular study

    by Parasto Atri, Flora Forouzesh, Ehsan Nazemalhosseini-Mojarad, Seyedeh Nasim Mirbahari, Claudia Cava

  • Preliminary Insights Into the Combined Antitumor Efficacy of Onco‐VV‐TT and Natural Killer Cells in Glioblastoma

    by Seyedeh Nasim Mirbahari, Davood Sanooghi, Marzieh Ebrahimi, Hamid Mahdizadeh, Ali Davari, Amir‐Abbas Hedayati Asl, Sahel Ahmadpour Torkamani, Mahdi Hesaraki, Mehdi Totonchi

    This study investigates the therapeutic efficacy and safety of Onco‐VV‐TT, a genetically engineered oncolytic vaccinia virus, in the treatment of glioblastoma (GBM), with and without the combination of natural killer (NK) cell immunotherapy. A comprehensive set of in vitro and in vivo experiments was conducted to assess viral cytotoxicity, replication, tumor penetration, and immunomodulatory effects. Onco‐VV‐TT selectively reduced the viability of GBM cell lines (U251, U87, and C6) in a time‐ and dose‐dependent manner while sparing normal fibroblasts. The virus significantly impaired clonogenicity, migration, and stemness‐related gene expression in U251 cells. Confocal imaging confirmed viral replication and deep penetration into 3D spheroids. NK cells demonstrated strong cytotoxicity against U251 cells in both 2D and 3D models. In a xenograft mouse model, intratumoral administration of Onco‐VV‐TT suppressed tumor growth and significantly prolonged survival; NK cell monotherapy showed limited efficacy, while the addition of NK cells further enhanced therapeutic outcomes. Immunological analyses revealed that combination therapy elevated pro‐inflammatory cytokines (TNF‐α, IFN‐γ, and IL‐6) and increased WBC count, reflecting an expected transient systemic inflammatory response to vaccinia virus exposure rather than a direct enhancement of antitumor immunity. Histopathological and immunohistochemical analysis showed reduced mitosis, increased apoptosis, decreased cancer stem cell marker CD133, and lower VEGF expression in tumors treated with Onco‐VV‐TT and NK cells. Safety evaluations in immunocompetent mice demonstrated no significant systemic toxicity or organ damage following intravenous injection of Onco‐VV‐TT. Transient inflammatory marker elevation resolved by day 21, and all hematological and biochemical parameters remained within normal range. These findings suggest that Onco‐VV‐TT, particularly in combination with NK cell therapy, is a promising and well‐tolerated approach for GBM treatment, meriting further preclinical and clinical development.

  • Open Access

    A Novel Treatment Schedule Combining Injectable Platelet‐Rich Fibrin and Endolift Laser for Facial Rejuvenation: A Case Report

    by Mohammad Ali Nilforoushzadeh, Pantea Bozorg Savoji, Tannaz Fakhim, Seyedeh Nasim Mirbahari

    The combination of Endolift laser therapy and injectable platelet‐rich fibrin (i‐PRF) is an emerging strategy in aesthetic medicine, but the optimal scheduling of these modalities remains unexplored. This case report highlights a novel treatment schedule combining i‐PRF and Endolift laser therapy, resulting in noticeable short‐term facial rejuvenation in a 56‐year‐old female. A 56‐year‐old woman presented with concerns regarding facial skin laxity and aging. A unique treatment schedule was implemented: i‐PRF injections were administered 1 day before (Day −1), 1 week after (Day +7), and 1 month after (Day +30) a single Endolift laser session (Day 0). At the 4‐week follow‐up, the patient demonstrated marked improvement in skin tightness, texture, and overall facial appearance, as assessed by clinical examination, standardized photography, and high patient‐reported satisfaction. Only mild, transient adverse effects were observed, with no delayed complications. This novel schedule combining i‐PRF and the Endolift laser demonstrates promising synergistic effects, resulting in significant short‐term skin rejuvenation. While these initial findings suggest that the precise timing of i‐PRF enhances the regenerative impact of Endolift therapy, further large‐scale studies utilizing objective measurement scales and extended follow‐up periods (3–6 months) are warranted to validate long‐term durability and establish standardized protocols.

  • Open Access

    Synergistic Effects of Endolift With Complementary Cosmetic Procedures: A Narrative Review and Comprehensive Approach

    by Mohammad Ali Nilforoushzadeh, Pantea Bozorg Savoji, Tannaz Fakhim, Shohreh Rafiei, Seyedeh Nasim Mirbahari

    Background: The landscape of aesthetic medicine has increasingly favored minimally invasive interventions, with the 1470 nm diode laser (Endolift) gaining prominence as a viable alternative to surgical lifting for soft‐tissue remodeling and lipolysis. Aims: This narrative review synthesizes current evidence on the mechanism, clinical versatility, and safety profile of Endolift. A primary objective is to evaluate the synergistic potential of combining this technology with complementary aesthetic modalities to optimize patient outcomes. Patients/Methods: A comprehensive search of PubMed/MEDLINE, Scopus, and Google Scholar was conducted. We analyzed key literature on the 1470 nm diode laser, selecting studies that document its efficacy as monotherapy and in combination with injectables or regenerative techniques. Results: The 1470 nm wavelength exhibits high affinity for water, facilitating selective lipolysis and stimulating deep collagen restructuring through controlled photothermal interaction. Clinical findings consistently report tangible improvements in skin laxity and contouring with limited recovery time. Notably, multimodal protocols—integrating dermal fillers, nanofat, or surface resurfacing—appear to enhance aesthetic outcomes by simultaneously addressing volume deficits and superficial texture alongside tissue tightening. Conclusions: Endolift represents a robust, minimally invasive tool for facial and body sculpting. While current data support its efficacy, particularly within multimodal treatment plans, the standardization of protocols through larger, randomized controlled trials remains a priority to confirm long‐term durability.


  • Open Access

    Regenerative Scalp Preparation With Stromal Vascular Fraction and Platelet‐Rich Fibrin Prior to Hair Transplantation in Lichen Planus: A Case Report

    by Pantea Bozorg Savoji, Seyedeh Nasim Mirbahari, Shohreh Rafiee, Tannaz Fakhim, Mohammad Ali Nilforoushzadeh

    Lichen planus (LP) is a chronic inflammatory scalp disorder that can lead to cicatricial alopecia, making it challenging for hair transplantation. This case report describes a 26‐year‐old female with LP who underwent scalp preparation using SVF and PRF before hair transplantation. SVF was administered 6 weeks prior, followed by PRF 4 weeks before the procedure to enhance scalp vascularization and reduce inflammation. After 1 year of follow‐up, significant graft survival and improved scalp condition were observed without major complications. This report highlights the potential of SVF and PRF in optimizing hair transplantation outcomes for patients with LP.

  • Open Access

    Staged Regenerative Salvage of Post-Rhinoplasty Nasal Necrosis Using Nanofat, Platelet-Rich Fibrin (PRF), and an Autologous Fat Membrane: A Case Report

    by Mohammad Ali Nilforoushzadeh, Pantea Bozorg Savoji, Masoomeh Mohammadi, Seyedeh Nasim Mirbahari

  • Open Access

    A Novel Treatment Schedule Combining Platelet-Rich Fibrin and Endolift Laser for Facial Rejuvenation: A Case Report

    by Mohammad Ali Nilforoushzadeh, Pantea Bozorg Savoji, Seyedeh Nasim Mirbahari, Tannaz Fakhim

  • Open Access

    Regenerative Scalp Preparation with Stromal Vascular Fraction and Platelet Rich Fibrin Prior to Hair Transplantation in Lichen Planus: A Case Report

    by Pantea Bozorg Savoji, Seyedeh Nasim Mirbahari, Tannaz Fakhim, Shohreh Rafiee, Mohammad Ali Nilforoushzadeh1

  • Open Access

    Unmasking the potential: mechanisms of neuroinflammatory modulation by oncolytic viruses in glioblastoma

    by Narimene Beder, Seyedeh Nasim Mirbahari, Mourad Belkhelfa, Hamid Mahdizadeh, Mehdi Totonchi

    Glioblastoma, an aggressive and lethal brain tumor, presents enormous clinical challenges, including molecular heterogeneity, high recurrence rates, resistance to conventional therapies, and limited therapeutic penetration across the blood-brain barrier. The glioblastoma microenvironment, characterized by a dynamic interplay of cellular and non-cellular components, is a key driver of tumor growth and therapeutic resistance. Neuroinflammatory cytokines, particularly interleukins and tumor necrosis factor-alpha, play pivotal roles in this microenvironment, contributing to tumor progression and immune evasion. This review highlights oncolytic virotherapy as a promising therapeutic avenue, focusing on its potential to modulate neuroinflammatory responses, induce localized immune reactions, and deliver immunomodulatory factors directly to the tumor site. While encouraging outcomes have been observed, challenges such as overcoming the blood-brain barrier, managing host antiviral immunity, and mitigating potential risks to normal neuronal cells remain critical barriers to clinical translation. By analyzing the intricate interactions of oncolytic viruses with the glioblastoma microenvironment and synthesizing findings from preclinical and clinical trials, this review provides actionable insights into developing personalized and effective therapeutic strategies for this aggressive tumor based on oncolytic virotherapy alone or when using it combined with conventional therapies, immunotherapy, natural killer-cell therapy, chimeric antigen receptor-T cell therapy, and dendritic cell therapy.


  • Open Access

    Oncolytic Viruses Reshape PD‐1/PD‐L1 Signaling: Mechanisms and Clinical Synergy With Immune Checkpoint Blockade

    by Seyedeh Nasim Mirbahari, Mehdi Bakhtiyaridovvombaygi, Hamid Mahdizadeh, Amirhossein Izadpanah, Elham Roshandel, Mehdi Totonchi

    Oncolytic viruses (OVs) are naturally occurring or genetically engineered viruses that selectively target and destroy cancer cells. They act through multiple mechanisms, including direct tumor cell lysis, stimulation of immune‐mediated cytotoxicity, and modulation of the tumor microenvironment (TME). Recent studies have shown that, beyond their direct oncolytic activity, OVs also influence the immune landscape by modulating the expression of PD‐1/PD‐L1 axis. In many cases, OVs trigger the release of proinflammatory cytokines, leading to increased PD‐L1 levels on immune cells. This upregulation plays a key role in modulating the TME and shaping immune checkpoint signaling. While there is also evidence that OVs can directly reduce PD‐L1 expression on tumor cells, the most prominent effect appears to be the boost in PD‐L1 expression. This shift is thought to be crucial in influencing how the immune system responds to tumors. These changes could modulate PD‐L1‐mediated immune suppression and alter the exhaustion and anergy rate of the effector tumor‐specific T cells infiltrated into the TME. This review discusses how OVs influence PD‐1 and PD‐L1 expression, with a focus on innate and adaptive immune activation, interferon signaling pathways, and engineered OVs designed to express immunomodulatory cytokines and chemokines. We explore how these mechanisms can be leveraged to enhance antitumor immunity, particularly in combination with ICIs. Furthermore, we discuss the potential of OVs to remodel the TME, modulate PD‐L1 expression, and promote immune‐mediated tumor clearance. Overall, this review highlights the evolving role of OVs in cancer therapy and their potential to augment the effectiveness of current immunotherapeutic strategies.